• Shoulder Innovations’ third-quarter 2026 net loss narrowed 20% year-over-year to $7 million; net revenue climbed 38% to $16.2 million.
• Research and development expenses more than doubled to $3.2 million, driven by new-product development, including substantial work on the InSet Neo robotic platform.
• The company completed initial surgeries with its InSet Go glenoid implant and launched its FDA-cleared N-22 humeral head.
• Full-year 2026 net revenue guidance rose to $68 million–$70 million from $67 million–$69 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shoulder Innovations Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001699350-26-000062), on November 05, 2026, and is solely responsible for the information contained therein.